FR2856688B1 - PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX - Google Patents

PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX

Info

Publication number
FR2856688B1
FR2856688B1 FR0307649A FR0307649A FR2856688B1 FR 2856688 B1 FR2856688 B1 FR 2856688B1 FR 0307649 A FR0307649 A FR 0307649A FR 0307649 A FR0307649 A FR 0307649A FR 2856688 B1 FR2856688 B1 FR 2856688B1
Authority
FR
France
Prior art keywords
association
product
cancer agent
phosphatase inhibitor
another cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0307649A
Other languages
English (en)
French (fr)
Other versions
FR2856688A1 (fr
Inventor
Gregoire Prevost
Pannetier Marie Christi Brezak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to FR0307649A priority Critical patent/FR2856688B1/fr
Priority to MYPI20042361A priority patent/MY141725A/en
Priority to MXPA06000216A priority patent/MXPA06000216A/es
Priority to JP2006516322A priority patent/JP2007514639A/ja
Priority to PCT/FR2004/001586 priority patent/WO2005000852A2/fr
Priority to DE602004022674T priority patent/DE602004022674D1/de
Priority to CA002530668A priority patent/CA2530668A1/fr
Priority to US10/562,625 priority patent/US20060281736A1/en
Priority to AT04767442T priority patent/ATE439836T1/de
Priority to EP04767442A priority patent/EP1641453B1/fr
Priority to EP08020152A priority patent/EP2335702A1/fr
Priority to EP07006144A priority patent/EP1792905A1/fr
Priority to ES04767442T priority patent/ES2332137T3/es
Priority to PL04767442T priority patent/PL1641453T3/pl
Priority to DK04767442T priority patent/DK1641453T3/da
Priority to ARP040102257A priority patent/AR044930A1/es
Publication of FR2856688A1 publication Critical patent/FR2856688A1/fr
Priority to US12/154,319 priority patent/US20090253685A1/en
Application granted granted Critical
Publication of FR2856688B1 publication Critical patent/FR2856688B1/fr
Priority to US12/247,072 priority patent/US20090137596A1/en
Priority to ARP090100837A priority patent/AR070977A2/es
Priority to JP2009091214A priority patent/JP2009149694A/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0307649A 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX Expired - Fee Related FR2856688B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
MYPI20042361A MY141725A (en) 2003-06-25 2004-06-17 Product comprising at least one cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent
PL04767442T PL1641453T3 (pl) 2003-06-25 2004-06-24 Produkt obejmujący co najmniej jeden inhibitor fosfatazy Cdc25 w kombinacji z co najmniej jednym innym środkiem przeciwnowotworowym
PCT/FR2004/001586 WO2005000852A2 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux
DE602004022674T DE602004022674D1 (de) 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25-phosphatase inhibitor und mindestens ein anderes anti-krebs mittel
CA002530668A CA2530668A1 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphatase cdc25 en association avec au moins un autre agent anti-cancereux
US10/562,625 US20060281736A1 (en) 2003-06-25 2004-06-24 Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
AT04767442T ATE439836T1 (de) 2003-06-25 2004-06-24 Zusammensetzung die mindestens ein cdc25- phosphatase inhibitor und mindestens ein anderes anti-krebs mittel
EP04767442A EP1641453B1 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux
EP08020152A EP2335702A1 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphatase Cdc25 en association avec au moins un autre agent anti-cancéreux
MXPA06000216A MXPA06000216A (es) 2003-06-25 2004-06-24 Producto que comprende por lo menos un inhibidor de cdc25 fosfatasa en combinacion con al menos algun otro agente anti-cancer.
ES04767442T ES2332137T3 (es) 2003-06-25 2004-06-24 Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso.
JP2006516322A JP2007514639A (ja) 2003-06-25 2004-06-24 少なくとも１の他の抗癌剤と組み合わせた少なくとも１のＣｄｃ２５ホスファターゼ阻害剤を含有する製品
DK04767442T DK1641453T3 (da) 2003-06-25 2004-06-24 Produkt, der indeholder i det mindste en CDC25-phosphatase-inhibitor, i kombination med i det mindste et andet anti-cancer-middel
EP07006144A EP1792905A1 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphatase CDC25 en association avec au moins un autre agent anti-cancéreux
ARP040102257A AR044930A1 (es) 2003-06-25 2004-06-25 Producto que comprende al menos un inhibidor de cdc25 fosfatasa en combinacion con al menos un agente anticancerigeno adicional
US12/154,319 US20090253685A1 (en) 2003-06-25 2008-05-22 Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent
US12/247,072 US20090137596A1 (en) 2003-06-25 2008-10-07 G-protein inhibitor
ARP090100837A AR070977A2 (es) 2003-06-25 2009-03-09 Compuesto (1r)-1-[({(2r)-2-amino-3-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-3-oxopropil}ditio)metil]-2-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-2-oxoetilamina y sus sales, proceso para su preparacion, composicion farmaceutica y
JP2009091214A JP2009149694A (ja) 2003-06-25 2009-04-03 少なくとも１の他の抗癌剤と組み合わせた少なくとも１のＣｄｃ２５ホスファターゼ阻害剤を含有する製品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX

Publications (2)

Publication Number Publication Date
FR2856688A1 FR2856688A1 (fr) 2004-12-31
FR2856688B1 true FR2856688B1 (fr) 2008-05-30

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0307649A Expired - Fee Related FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX

Country Status (14)

Country Link
US (3) US20060281736A1 (enExample)
EP (3) EP1792905A1 (enExample)
JP (2) JP2007514639A (enExample)
AR (2) AR044930A1 (enExample)
AT (1) ATE439836T1 (enExample)
CA (1) CA2530668A1 (enExample)
DE (1) DE602004022674D1 (enExample)
DK (1) DK1641453T3 (enExample)
ES (1) ES2332137T3 (enExample)
FR (1) FR2856688B1 (enExample)
MX (1) MXPA06000216A (enExample)
MY (1) MY141725A (enExample)
PL (1) PL1641453T3 (enExample)
WO (1) WO2005000852A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8222342B2 (en) * 2007-09-06 2012-07-17 Basf Se Blends from branched polyaryl ethers and hydrophilic polymers
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
HUE042801T2 (hu) 2010-11-12 2019-07-29 Pharma Mar Sa Kombinációs terápia mitózisgátlóval
TWI791515B (zh) 2017-04-24 2023-02-11 瑞士商諾華公司 治療療法
US20210106567A1 (en) * 2019-10-01 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
EP1233787B8 (fr) * 1999-11-09 2005-05-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
CA2432417A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
ES2332137T3 (es) 2010-01-27
EP1792905A1 (fr) 2007-06-06
JP2007514639A (ja) 2007-06-07
JP2009149694A (ja) 2009-07-09
WO2005000852A2 (fr) 2005-01-06
DE602004022674D1 (de) 2009-10-01
EP1641453A2 (fr) 2006-04-05
DK1641453T3 (da) 2009-12-14
ATE439836T1 (de) 2009-09-15
EP2335702A1 (fr) 2011-06-22
US20090137596A1 (en) 2009-05-28
AR070977A2 (es) 2010-05-19
CA2530668A1 (fr) 2005-01-06
US20060281736A1 (en) 2006-12-14
MXPA06000216A (es) 2006-04-11
MY141725A (en) 2010-06-15
PL1641453T3 (pl) 2010-01-29
EP1641453B1 (fr) 2009-08-19
AR044930A1 (es) 2005-10-12
US20090253685A1 (en) 2009-10-08
WO2005000852A3 (fr) 2005-06-30
FR2856688A1 (fr) 2004-12-31

Similar Documents

Publication Publication Date Title
FR2856688B1 (fr) PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
MX2008006580A (es) Composicion de cereal que comprende edulcorante de alta potencia
FR2881508B1 (fr) Distributeur d'agent lubrifiant
EP1694640A4 (en) ANTI CANCER AGENTS
DE602004014610D1 (de) Fluidproduktspender
DE602004008340D1 (de) Fluidproduktspender
EP1894574A4 (en) ANTICROBIAL AGENTS WITH PROTEIN C INHIBITOR
DE602004026636D1 (de) Fluidproduktabgabeglied
NO20052429D0 (no) Konstrastmidler
DE602004011428D1 (de) Produktabgabeanordnung
ES1058246Y (es) Caja de distribucion.
NL1026828A1 (nl) Derivaten van azachinazoline.
SK3667U (sk) Cereálna tyčinka
ES1058247Y (es) Caja de distribucion.
BR0202836B1 (pt) equipamento de abastecimento de produtos lìquidos.
ES1053104Y (es) Monopatin de ruedas en linea.
ES1051964Y (es) Enganche para conexion de herramientas o maquinas retroexcavadoras y similares.
TH40727S1 (th) รถแทรคเตอร์
TH108645S (th) รถแทรคเตอร์
ES1057388Y (es) Caja isotermica.
ES1056508Y (es) Caja.
ES1056188Y (es) Emisor de ultrasonidos.
ES1048412Y (es) Caja de herramientas.
ES1048580Y (es) Caja de herramientas.
ES1057884Y (es) Caja de condicionamiento espacial.

Legal Events

Date Code Title Description
CA Change of address
CD Change of name or company name
ST Notification of lapse

Effective date: 20130228